Selux Diagnostics Announces Additional $48 Million in Funding

Selux Diagnostics, Inc., a Boston-based biotech startup, announced an additional funding of $48 million for the commercialization of their Selux Next Generation Phenotyping (NGP) System in the United States. This comes after the company received its third FDA 510(k) clearance, marking them as the unique provider of a single-platform technology for rapid Antibiotic Susceptibility Testing (AST) from both positive blood culture and isolated colonies.

The funding round was led by RA Capital Management, with contributions from Northpond Ventures, Sands Capital, and Schooner Capital. The Selux NGP System is designed to deliver AST results significantly faster than the traditional 3-5 days, aiming for same-day results. This innovation is expected to enhance patient care by allowing for more precise antibiotic therapy, reducing the use of broad-spectrum antibiotics, and ultimately combating the rise of superbugs.

Steve Lufkin, CEO of Selux Diagnostics, expressed gratitude towards their partners and the Selux team for their roles in pioneering what he describes as a new era in personalized diagnostics through the NGP System. The system has gained notable support, including federal funding from the U.S. Department of Health and Human Services among others.